340 related articles for article (PubMed ID: 12063497)
1. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent.
Koss T; Bagheri B; Zeana C; Romagnoli MF; Grossman ME
J Am Acad Dermatol; 2002 Jun; 46(6):945-7. PubMed ID: 12063497
[TBL] [Abstract][Full Text] [Related]
2. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin.
Cooke FJ; Terpos E; Boyle J; Rahemtulla A; Rogers TR
Clin Microbiol Infect; 2003 Dec; 9(12):1238-41. PubMed ID: 14686991
[TBL] [Abstract][Full Text] [Related]
3. Successful combined antifungal salvage therapy with liposomal amphothericin B and caspofungin for invasive Aspergillus flavus infection in a child following allogeneic bone marrow transplantation.
Kriván G; Sinkó J; Nagy IZ; Goda V; Reményi P; Bátai A; Lueff S; Kapás B; Réti M; Tremmel A; Masszi T
Acta Biomed; 2006; 77 Suppl 2():17-21. PubMed ID: 16918062
[TBL] [Abstract][Full Text] [Related]
4. Invasive esophageal aspergillosis associated with acute myelogenous leukemia: successful therapy with combination caspofungin and liposomal amphotericin B.
Alioglu B; Avci Z; Canan O; Ozcay F; Demirhan B; Ozbek N
Pediatr Hematol Oncol; 2007; 24(1):63-8. PubMed ID: 17130115
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of five antifungal agents against 199 clinical and environmental isolates of Aspergillus flavus, an opportunistic fungal pathogen.
Khodavaisy S; Badali H; Hashemi SJ; Aala F; Nazeri M; Nouripour-Sisakht S; Sorkherizi MS; Amirizad K; Aslani N; Rezaie S
J Mycol Med; 2016 Jun; 26(2):116-121. PubMed ID: 26948143
[TBL] [Abstract][Full Text] [Related]
6. Caspofungin acetate for treatment of invasive fungal infections.
Pacetti SA; Gelone SP
Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
8. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
Groll AH; Walsh TJ
Expert Opin Investig Drugs; 2001 Aug; 10(8):1545-58. PubMed ID: 11772269
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin: first approved agent in a new class of antifungals.
Johnson MD; Perfect JR
Expert Opin Pharmacother; 2003 May; 4(5):807-23. PubMed ID: 12740003
[TBL] [Abstract][Full Text] [Related]
10. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
Aliff TB; Maslak PG; Jurcic JG; Heaney ML; Cathcart KN; Sepkowitz KA; Weiss MA
Cancer; 2003 Feb; 97(4):1025-32. PubMed ID: 12569602
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
12. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.
Cacciapuoti A; Halpern J; Mendrick C; Norris C; Patel R; Loebenberg D
Antimicrob Agents Chemother; 2006 Jul; 50(7):2587-90. PubMed ID: 16801452
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
14. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.
Sionov E; Mendlovic S; Segal E
J Antimicrob Chemother; 2005 Sep; 56(3):594-7. PubMed ID: 16006446
[TBL] [Abstract][Full Text] [Related]
15. Aspergillus flavus sinusitis in ALL.
Keane C; Colreavy M; Lynch M; O'Gorman P
Am J Hematol; 2009 Feb; 84(2):123. PubMed ID: 19253415
[No Abstract] [Full Text] [Related]
16. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
17. Aspergillus flavus scleritis: successful treatment with voriconazole and caspofungin.
Howell A; Midturi J; Sierra-Hoffman M; Carpenter J; Hurley D; Winn R
Med Mycol; 2005 Nov; 43(7):651-5. PubMed ID: 16396251
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
19. Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.
Olson JA; Schwartz J; Hahka D; George A; Proffitt RT; Adler-Moore JP
Antimicrob Agents Chemother; 2012 Jan; 56(1):218-30. PubMed ID: 21968353
[TBL] [Abstract][Full Text] [Related]
20. Cerebral aspergillosis diagnosed by detection of Aspergillus flavus-specific DNA, galactomannan and (1-->3)-beta-D-glucan in clinical specimens.
Khan ZU; Ahmad S; Mokaddas E; Said T; Nair MP; Halim MA; Nampoory MR; McGinnis MR
J Med Microbiol; 2007 Jan; 56(Pt 1):129-132. PubMed ID: 17172527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
